I5 Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-12-2024
- Paid Up Capital ₹ 0.50 M
as on 18-12-2024
- Company Age 15 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.70 M
as on 18-12-2024
- Revenue -94.80%
(FY 2022)
- Profit 80.85%
(FY 2022)
- Ebitda 100.00%
(FY 2022)
- Net Worth -2.08%
(FY 2022)
- Total Assets %
(FY 2022)
About I5 Clinical Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.70 M.
Yogesh Sharma and Thanigai Arasu serve as directors at the Company.
- CIN/LLPIN
U73100TN2009PTC073642
- Company No.
073642
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does I5 Clinical Research Private Limited offer?
I5 Clinical Research Private Limited offers a wide range of products and services, including Health Care Equipment, Research and Development (R&D) Work, Product Development Research, Health Care Service.
Who are the key members and board of directors at I5 Clinical Research?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thanigai Arasu  | Director | 01-Nov-2011 | Current |
| Yogesh Sharma | Director | 29-Jul-2017 | Current |
Financial Performance and Corporate Structure Insights of I5 Clinical Research.
I5 Clinical Research Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 94.8% decrease. The company also saw a substantial improvement in profitability, with a 80.85% increase in profit. The company's net worth dipped by a decrease of 2.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I5 Clinical Research?
Unlock access to I5 Clinical Research's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Idd Research Solutions Private LimitedActive 6 years 3 monthsYogesh Sharma and Thanigai Arasu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Feb 2013 | ₹0.70 M | Open |
How Many Employees Work at I5 Clinical Research?
Unlock and access historical data on people associated with I5 Clinical Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I5 Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I5 Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
